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Summary
A successful immune response requires intercellular contact between T and B lymphocytes . We
recently showed that CD28, aT cell surface protein that regulates an activation pathway, could
mediate intercellular adhesion with activated B cells by interaction with the B7 antigen . Here
we show that CD28 is the primary receptor for B7 on activated peripheral blood T cells, that
CD28 binds to B7 in the absence of other accessory molecules, and that interaction between
CD28 and B7 is costimulatory for T cell activation . To characterize the binding of CD28 to
B7, we have produced genetic fusions of the extracellular portions of B7 and CD28, and
immunoglobulin (Ig) Cy1 chains . 121I-labeled B7 Ig bound to CD28-transfected Chinese hamster
ovary (CHO) cells, and to immobilized CD28 Ig with a Kd -200 nM . B7 Ig also inhibited
CD28-mediated cellular adhesion . The function ofCD28-B7 interactions duringT cell activation
was investigated with soluble fusion proteins and with B7-transfected CHO cells. Immobilized
B7 Ig and B7+ CHO cells costimulated T cell proliferation . Stimulation of T cells with B7+
CHO cells also specifically increased levels ofinterleukin 2 transcripts. These results demonstrate
that theCD28 signaling pathway could be activated by B7, resulting in increasedT cell cytokine
production and T cell proliferation . Cellular interactions mediated byB7 andCD28 may represent
an important component of the functional interactions between T and B lymphoid cells.
I
t has long been known that interactions between T and
B lymphocytes play a central role in regulating an immune
response (1, 2) . More recent studies have shown that activa-
tion and differentiation ofboth T and B lymphocytes is de-
pendent upon direct intercellular (cognate) interactions be-
tween these cell types. While the specificity ofT. cell-B cell
interactions is determined by interaction between theTCR/
CD3 complex (3-5) and antigen associated with class IIMHC
molecules on B cells (6), interactions between other (acces-
sory) cell adhesion molecules are also necessary for a full im-
mune response (7-9) . Interactions between accessory receptors
and their counter-receptors may increase the avidity of cel-
lular interactions (7) ; control lymphocyte localization and
migration (10) ; and have direct signaling functions (7, 11,
12) during lymphocyte activation . Accessory receptors and
their counter-receptors involved in T-B cell interactions in-
clude (reviewed in reference 7) : CD2 and LFA3, CD4 and
class IIMHC molecules, LFA1, and ICAM-1 and ICAM-2 .
TheT cell homodimer, CD28, a member of the Ig super-
family (.13), has been shown in studies using mAbs to have
an accessory function during T cell activation (14) . Anti-CD28
mAbs have been shown to costimulate T cell proliferation
induced by a number of polyclonal stimuli (reviewed in ref-
erence 14) . ThesemAbs also inhibited alloantigen and soluble
antigen-specific T cell responses (15, 16), indicating that CD28-
mediated signalling may be crucial during these responses.
CD28-mediated T cell activation, unlike that initiated via
TCR, was resistant to inhibition by the immunosuppressive
agent, cyclosporine (17) . Some of the effects of anti-CD28
mAbs appear to result, in part, from the coordinate stimula-
tion of several T cell-derived cytokines (18) through stabili-
zation of their mRNAs (19) .
We recently reported that Chinese hamster ovary (CHO)1
cells transfected with CD28 mediated specific adhesion with
certain activated normal and malignant B cells (20) . CD28-
mediated adhesion was blocked by the mAb BB-1(21), which
recognizes the B cell activation antigen, termed B7, another
member of the Ig superfamily (22) . COS cells transfected
with a cDNA clone encoding B7 adhered specifically to
CD28+ CHO cells, thereby indicating that the B7 antigen
is a counter-receptor for CD28 .
'Abbreviations used in this paper . CHO, Chinese hamster ovary ; dhfr,
dihydrofolate reductase.
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regulate interaction of T andB lymphocytes . In this paper,
we have further characterized biochemical and functional
aspects of the interaction between these molecules. Fusion
proteins of B7 and CD28 with human Ig Cyl chains
were expressed and used to measure the specificity and ap-
parent affinity of their interaction . We have also used purified
B7Ig fusion protein, as well as CHO cells transfected with
B7 to investigate the functional importance of this interac-
tion on T cell activation and cytokine production .
Materials and Methods
Plasmid Construction .
￿
Expression plasmids containing cDNAs
encoding CD28 (13), CD5 (23), and B7 (22) have been described
previously . For initial attempts at expression of soluble forms of
CD28 and B7, constructs were made (OMCD28 and OMB7) in
which stop codons were introduced upstream of the transmem-
brane domains and the native signal peptides were replaced with
the signal peptidefrom oncostatinM (24) . Thesewere made using
synthetic oligonucleotides for reconstruction (OMCD28) or as
primers for PCR (OMB7) . CD28 Ig andB7 Ig fusion constructs
were made in two parts . The 5' portions were made usingOMCD28
and OMB7 as templates and the oligonucleotide, CTAGCCACT
GAAGCTTCACCATGGGTGTACTGCPCACAC, (corresponding
to the oncostatinMsignal peptide) as a forward primer, and either
TGGCATGGGCTCCTGATCAGGCTTAGAAGGTCCGGGAAA
or, TTTGGGCTCCTGATCAGGAAAATGCTCTTGCTTGGT
TGT as reverse primers, respectively. Products of thePCR reac-
tionswere cleaved with restriction endonucleases (HindIII and BclI)
at sites introduced in the PCR primers and gel purified .
The 3' portion of the fusion constructs corresponding to human
Ig Cyl sequenceswasmade by acoupled reverse transcriptase (from
Avian myeloblastosis virus ; Life Sciences Inc., St . Petersburg, FL)-
PCR reaction using RNA from a myeloma cell line producing
human-mouse chimeric mAb L6 (P. Fell andM. Gayle, unpub-
lished results) as template . The oligonucleotide, AAGCAAGA-
GCATTI"TCCTGATCAGGAGCCCAAATCTTCTGACAAAAC-
TCACACATCCCCACCGTCCCCAGCACCTGAACTCCTG,
was used as forward primer, and CTTCGACCAGTCTAGAA-
GCATCCTCGTGCGACCGCGAGAGC as reverse primer. Reac-
tion products were cleaved with BclI and Xbal and gel purified .
Final constructs were assembledby ligating HindIII/BcII cleaved
fragments containing CD28 or B7 sequences together with
Bc1I/XbaI cleaved fragment containing Ig Cyl sequences into Hind-
III/Xbal cleavedCDM8 . Ligation products were transformed into
MC1061/p3 cells and colonies were screened for the appropriate
plasmids. Sequencesof the resulting constructs were confirmedby
DNA sequencing (see Fig . 1) . CD5 Ig wasconstructed in identical
fashion, using CATTGCACAGTCAAGCTTCCATGCCCA'IG-
GGTTCTCTGGCCACCTTG, as forward primer andATCCAC-
AGTGCAGTGATCATTTGGATCCTGGCATGTGAC as reverse
primer. The PCR product was restriction endonuclease digested
and ligated with the Ig Cyl fragment as described above. The
resulting construct(CD5 Ig) encodes amature protein comprising
residues 1-347 of CD5, two amino acids introduced by the con-
struction procedure (amino acids DQ), followed by the Ig Cyl
hinge region as shown in Fig. 1.
PCRreactions (0 .1 ml final volume) were run in Taq polymerase
buffer (Stratagene, Torrey Pines, CA), containing 20 umol each
dNTP; 50-100pmol of theindicated primers; template (1 ng plasmid
orcDNA synthesized from 41 wg total RNA usingrandom hex-
722
￿
Binding of B7 to CD28
amer primer); and Taq polymerase (Stratagene) . Reactions were
run on a thermocycler (Perkin Elmer Corp ., Norwalk, CT) for
16-30 cycles (a typical cycle consisted of steps of 1 min at 94°C,
2 min at 50°C, and 3 min at 72°C) .
Immunostaining andFACS Analysis.
￿
Transfected CHO cells or
activated T cells were analyzed by indirect immunostaining . Be-
fore staining, CHO cells were removed from their culture vessels
by incubation in PBS containing 10 mM EDTA . Cells were first
incubated with murine mAbs 9.3 (25) or BB-1 (21), or with Ig
fusion proteins (all at 10 wg/ml in DMEM . containing 10% FCS)
for 1-2 h at 4°C . Cells were then washed, and incubated for an
additional 0.5-2 h at4°Cwith a FITC-conjugated second step re-
agent (goat anti-mouse Ig serum for murine mAbs, or goat
anti-human Ig Cy serum for fusion proteins ; Tago, Inc., Burlin-
game, CA) . Fluorescence was analyzed on a FACS IV'* cell sorter
(Becton Dickinson and Co ., Mountain View, CA) equipped with
a four decade logarithmic amplifier.
Cell Culture and Transfections.
￿
Stable transfectants expressing
CD28, CD5, or B7 were isolated following cotransfection of di-
hydrofolate reductase-deficient Chinese hamster ovary (dhfr-
CHO) cells with amixture of the appropriate expression plasmid
andthe selectable marker, pSV2dhfr (20) . Transfectants were then
grown in increasing concentrations of methotrexate to a final level
of 1 PM. Lines expressing high levels of CD28 (CD28' CHO)
or B7 (B7' CHO) were isolated by multiple rounds of fluor-
escence-activated cell sorting following indirect immunostaining
with mAbs 9.3 or BB-1 . AmplifiedCHO cells negative for surface
expression of CD28 or B7 (dhfr' CHO) were also isolated by
fluorescence-activated cell sorting from CD28-transfected popu-
lations .
COS cells were transfected with expression plasmids using a
modification of the protocol of Seed and Aruffo (26) . Cells were
seeded at 106 per 10 cm diameter culture dish 18-24 h before
transfection . PlasmidDNAwasadded (-15 FAg/dish) in a volume
of 5 mls of serum-freeDMEM containing 0.1 mM cloroquine and
600,ug/ml DEAE Dextran, and cells were incubated for 3-3.5 h
at 37°C . Transfected cells were then briefly treated (-2 min) with
10% dimethyl sulfoxide in PBS and incubated at 37°C for 16-24 h
inDMEM containing 10% FCS. At -24h after transfection, cul-
ture medium was removed and replaced with serum-free DMEM
(6 ml/dish) . Incubation was continued for 3 d at 37°C, at which
time the spentmedium was collected and fresh serum-free medium
was added . After an additional 3 d at 37°C, the spent medium
was again collected and cells were discarded.
Purification ofIg Fusion Proteins.
￿
The first and second collec-
tions of spent serum-free culture mediafrom transfected COS cells
were used as source for the purification ofIg fusion proteins . After
removal of cellular debris by low speed centrifugation, medium
was applied to a column (-200-400 ml medium/ml packed bed
volume) of immobilized protein A (Repligen Corp ., Cambridge,
MA) equilibrated with 0.05 M sodium citrate, pH 8.0. After ap-
plication of the medium, thecolumn waswashed with 1M potas-
sium phosphate,pH 8, andboundprotein was eluted with 0.05 M
sodium citrate, pH 3 . Fractions were collected and immediately
neutralized by addition of 1/10 volume of2M Tris, pH 8 . Frac-
tions containing the peak of Ano absorbing material were pooled
and dialyzed againstPBS before use . Extinction coefficients of 2.4
and 2.8 ml/mg for CD28 Ig and B7 Ig, respectively, by amino
acid analysis of solutions ofknown absorbance. The recovery of
purified CD28 Ig and B7 Ig binding activities were nearly quan-
titative asjudgedbyFACS® analysis after indirect fluorescent staining
of B7` and CD28' CHO cells .
Cell Separation andStimulation .
￿
PBL were isolated by centrifu-gation through Lymphocyte Separation Medium (Litton Bionetics,
Kensington, MD) and cultured in 96-well, flat-bottomed plates (4
x 104 cells/well, in a volume of0.2 ml) in RPMI containing 10%
FCS. Cellular proliferation ofquadruplicate cultures was measured
by uptake of [3H]thymidine during the last 5 h of a 3-d culture.
PHAactivated T cells were preparedby culturing PBL with 1 1&g/ml
PHA (Wellcome, Charlotte, NC) for 5 d, and 1 d in medium
lackingPHA . Viable cells were collected by sedimentation through
Lymphocyte Separation Medium before use .
Cell Surface Iodination and Immunoprecipitation.
￿
PHA-activated
T cells were cell-surface labeled with 1251 using lactoperoxidase and
H202 (27) . Nonionic detergent extracts oflabeled cells were pre-
pared and subjected to immunoprecipitation analysis as described
previously (28).
Radiolabeling ofB7 Ig .
￿
Purified B7 Ig (25 Fog) in a volume of
0.25 in] of0.12M sodium phosphate, pH 6.8 was iodinated using
2 mCi 1211 and 10 wg of chloramine T After 5 min at 23°C, the
reaction was stopped by the addition of20 hg sodium metabisulfite,
followed by 3 mg of KI and 1 mg of BSA. Iodinated protein was
separated from unreacted 1251 by chromatography on a 5-ml column
of Sephadex G-10 equilibrated with PBS containing 10% FCS.
Peak fractions were collected and pooled . The specific activity of
1251-B7 Ig labeled in this fashion was 1.5 x 106 cpm/pmol (2.8
x 10 7 cpm/i&g) .
B7 Ig was also metabolically labeled with [3sS]methionine. COS
cells were transfected with a plasmid encoding B7 Ig as described
above. At 24 h after transfection, [35S]methionine (>800 Ci/mmol ;
Amersham Corp., Arlington Heights, IL) was added to concen-
trations of 1151ACi/ml) in DMEM containing 10% FCS and 10%
normal levels of methionine. After incubation at 37°C for 3 d,
medium was collected and used for purification of B7 Ig as de-
scribed above. Concentrations of [35S]methionine-labeled B7 Ig
were estimated by comparison of staining intensity after SDS-PAGE
with intensities ofknown amounts ofunlabeled B7 Ig. The specific
activity of [35S]methionine-labeled B7 Ig was -2 x 10 6 cpm/Ug.
Binding Assays.
￿
For assays using immobilized CD28Ig, 96-well
plastic dishes were coated for 16-24 h with a solution containing
CD28Ig (0.5 jig in a volume of 0.05 ml of 10 mM Tris, pH 8) .
Wells were then blocked with binding buffer (DMEM containing
50mM BES, pH 6.8, 0.1% BSA, and 10% FCS) (Sigma Chemical
Co ., St . Louis, MO) before addition of a solution (0.09 ml) con-
taining 1251-B7 Ig (-3 x 106 cpm) or [3IS]-B7 Ig (1.5 x 10 5 cpm)
in the presence or absence ofcompetitor. After incubation for 2-3 h
at 23°C, wells were washed once with binding buffer, and four
times with PBS. Bound radioactivity was then solubilized by addi-
tion of 0.5 N NaOH, and quantified by liquid scintillation or y
counting. When binding of 1251-B7 to CD28* CHO cells was
measured, cells were seeded (2.5 x 104/well) in 96-well plates
16-24 h before the start ofthe experiment . Binding was otherwise
measured as described above.
SDS Page
￿
SDS-PAGE was performed on linear acrylamide gra-
dient gels with stacking gels of5% acrylamide. Gels were stained
with Coomassie Blue, destained, and photographed or dried and
exposed to X-ray film (KodakXAR5 ; Eastman KodakCo., Roch-
ester, NY) .
RNA BlotAnalysis.
￿
RNA was prepared from stimulatedPHA
blasts by a published procedure (29) . Aliquots of RNA (20 Fog)
were fractionated on formaldehyde agarose gels and then transferred
to nitrocellulose by capillary action . RNA was crosslinked to the
membrane by UV light in a Stratalinker (Stratagene), and the blot
was prehybridized and hybridized with a 32P-labeled probe for
human IIr2 (prepared from a -600-bpcDNA fragment provided
by Dr. S. Gillis ; Immunex Corp ., Seattle, WA) . Equal loading of
723
￿
Linsley et al.
RNA samples was verified both by rRNA staining and by hybrid-
ization with a rat glyceraldehyde-6-phosphate dehydrogenase probe
(GAPDH, a -1.2-kb cDNA fragment provided by Dr. A . Pur-
chio, Oncogen) .
Results
Construction and Expression ofB7 and CD28 Immunoglob-
ulin Cy Fusion Proteins. In initial attempts to make soluble
derivative ofB7 and CD28, we made cDNA constructs en-
coding molecules truncated at the NH2-terminal side of their
transmembrane domains . In both cases, the native signal pep-
tides were replaced with the signal peptide from oncostatin
M (24), which mediates efficient release of secreted proteins
in transient expression assays (J . Kallestad, P. S . Linsley, and
W Brady, unpublished observations) . These cDNAs were
cloned into an expression vector, transfected into COS cells,
and spent culture medium was tested for secreted forms of
B7 and CD28 . In this fashion, we produced several soluble
forms of B7, but in repeated attempts, we were unable to
detect soluble CD28 molecules .
We then took the approach of making receptor Ig Cy fu-
sion proteins. Other investigators (23, 30) have shown these
molecules to be efficiently produced in transient expression
systems, and easily purified and detected using standard im-
munochemical techniques. The B7 and CD28 extracellular
regions, preceded by the signal peptide to oncostatinM, were
fused in frame to an Ig C-yl cDNA, as shown in Fig . 1 A .
During construction, the Ig hinge disulfides were mutated
to serine residues to abolish intrachain disulfide bonding . The
resulting fusion proteins were produced in COS cells and
purified by affinity chromatography on immobilized protein
A as described in Materials and Methods. Yields of purified
protein were typically 1.5-4.5 mg/liter of spent culture
medium .
As shown in Fig . 1 B, the B7 Ig fusion protein migrated
during SDS-PAGE under nonreducing conditions predomi-
nantly as a single species ofM, 70,000, with a small amount
of material migrating as aMr -150,000 species . After reduc-
tion, a single M, -75,000 species was observed . The nature
of the M* -150,000 species was not investigated further.
CD28 Ig migrated as a Mr -140,000 species under non-
reducing conditions and aM -70,000 species after reduc-
tion, indicating that it was expressed as a homodimer. Since
the IgCyl hinge cysteines had been mutated, disulfide linkage
probably involved cysteine residues which naturally form in-
terchain bonds in the CD28 homodimer (25) .
Binding Activities ofB7 and CD28 Immunoglobulin Cy Fu-
sion Proteins. To investigate the functional activities of B7
Ig and CD28 Ig, we first tested binding to CHO cell lines
expressing CD28 or B7 . In early experiments, spent culture
media from transfected COS cells was used as a source of
fusion protein, while in later experiments, purified proteins
were used (Fig. 2) . Binding was detectedby addition of FITC-
conjugated goat anti-human Ig second step reagent . B7 Ig
was bound by CD28+ CHO, while CD28 Ig was bound
by B7+ CHO. B7 Ig also bound weakly to B7+ CHO (Fig.
2), suggesting that this molecule has a tendency to formFigure 1 .
￿
Construction and expression of B7 and CD28 Ig Cy fusion
proteins . (A) Maps of B7 Ig and CD28 Ig constructs. cDNA constructs
encoding the indicated portions of oncostatinM (dark shaded regions), B7
and CD28 (unshaded regions), and human Ig Cy1 (stippled regions) were
constructed as described in Materials and Methods. Sequences displayed
show the junctions between B7 and CD28 (capital letters), and the signal
peptide (SP) of oncostatin M at their NH2 termini, and the hinge (H)
of Ig Cyl at theirCOOH termini. Amino acids introduced during con-
struction are indicated in parentheses . Asterisks denote cysteine to serine
mutations introduced in the hinge . Boxes labeled V and C denote Ig
superfamily-like domains present in CD28 (13) and B7 (22) . The CH2
and CH3 domains of Ig Cyl are also indicated . (B) Purification of B7
Ig and CD28 Ig. Expression plasmid constructs encoding the fusion pro-
teins displayed above were transfected into COS cells . Serum-free condi-
tioned medium was collected, and Ig Cy-containingproteins were purified
byprotein A affinity chromatography as described in Materials and Methods.
Aliquots (1 ttg) of B7 Ig (lanes 1 and 3) or CD28 Ig (lanes 1 and 4) were
subjected to SDS-PAGE (4-12% acrylamide gradient) under nonreducing
(- RME, lanes 1 and 2) or reducing (+ ,QME lanes 3 and 4) conditions.
Lane 5 shows mol wt markers . Proteins were visualized by staining with
Coomassie Brilliant Blue.
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B7 Igand CD28 Ig bind to transfectedCHOCells.
￿
Amplified
transfected CHO cells expressing CD28, B7, or dhfr only (no surface
marker) were first stained with human Ig Cyl-containing proteins (chi-
meric mAb L6, CD28 Ig, B7 Ig, or CD5 Ig), or mouse mAbs (9.3 or
BB-1 at 10 gg/ml), followed by FITC-conjugated anti-human or mouse
Ig second step reagents . A total of 10,000 stained cells was then analyzed
by FACS® .
homophilic interactions. No binding was detected of a chi-
meric mAb containing human Ig Cy1, or of another fusion
protein, CD5 Ig. Thus, B7 Ig and CD28 Ig retain binding
activity for their respective counter-receptors .
We next determined the apparent affinity of interaction
between B7 and CD28 . B7 Ig was either metabolically la-
beled with [35S]methionine, or iodinated, and radiolabeled
derivatives were tested for binding to immobilized CD28 Ig
or to CD28+ CHO cells. A competition binding experi-
ment using 1251-B7 Ig and immobilized CD28 Ig is shown
in Fig . 3 A . Binding of 1251-B7 Ig was competed in dose-
dependent fashion by unlabeled B7 Ig, and bymAbs 9.3 and
BB-1 . mAb 9.3 was the most effective competitor (half-max-
imal inhibition at 4.3 nM), followed by mAb BB-1 (half-
maximal inhibition at 140 nM) and B7 Ig (half-maximal in-
hibition at 280 nM) . Thus, mAb 9.3 was -65-fold more
effective as a competitor than B7 Ig, indicating that themAb
has greater apparent affinity for CD28 . The same relative differ-
ence in avidities was seen when [35S]methionine-labeled B7
Ig was used . Chimeric mAb L6 did not significantly inhibit
binding; the inhibition at high concentrations in Fig. 3 A
was not seen in other experiments . When the competition
data were plotted in the Scatchard representation (Fig . 3 B),
a single class of binding sites was observed (Kd -200 nM) .
An identical Kd was detected for binding of 1251-B7 Ig to
CD28+ CHO cells . Thus, both membrane bound CD28
and immobilized CD28 Ig showed similar apparent affinities
for 1251-B7 .
CD28 is the Primary B7-binding Protein on PHA-activated T
CA. Although B7 Igbound to immobilized CD28 Ig, and
to CD28+ CHO cells, it was not known whether B7 Ig
could bind to CD28 naturally expressed on T cells . This is
, M10,LL
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1251-labeled B7 Ig binds with high affinity to immobilized
CD28 Ig. (A) Competition binding analysis of 1ZI-B7 Ig. 96-well plastic
dishes were coated with CD28 Ig as described in Materials and Methods.
1251-labeled B7 Ig (3.3 x 106 cpm, 2 x 106 cpm/pmol) was then added
to a concentration of 24 nM in the presence of the indicated concentra-
tions of unlabeled chimeric L6, mAb 9.3, mAb BB-1, or B7 Ig. Plate-
bound radioactivity was determined and is expressed as a percentage of
radioactivity bound to wells treated without competitor (7,800 cpm) . Each
point represents the mean of duplicate determinations; replicates generally
varied from the mean by <20%. Concentrations were calculated based
on aM of 75,000 per binding site for mAbs and 51,000 per binding site
for B7 Ig. (B) Scatchard analysis ofunlabeled B7 Ig competition binding
experiment. Data shown in Fig . 3A was replotted in the Scatchard represen-
tation and a binding constant (Kd) was estimated from the slope of the
line best fitting the experimental data (r = -0.985) .
an important consideration since the level ofCD28 on trans-
fected cells was -10-fold higher than that found on PHA-
activated T cells (20) . We therefore tested PHA-activated T
cells for binding of B7 Ig by FACS® analysis after indirect
immunofluorescent staining. As shown in Fig . 4 A, these
cells bound significant levels ofB7 Ig, and binding was in-
hibited by mAbs 9.3 and BB-1 We also determined the iden-
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Figure 4 .
￿
CD28 is the primary B7 Igbinding protein on PHA-activated
T cells . (A) FACS® profiles ofB7 Igbinding toPHAblasts . PHAstimulated
PBL were stained without or with B7 Ig at 10 pg/ml. Where indicated
mAbs 9 .3 or BB-1 were added (also at 10 Wg/ml) to cells simultaneously
with B7 Ig . Bound mAb was detected with a FITC-conjugated goat
anti-human Ig Cy reagent, and stained cells were analyzed by FACS®.
(B) Autoradiogram of 12SI-labeled proteins immunoprecipitated by B7 Ig.
PHA-stimulated PBL were surface labeled with 1251 as described in Ma-
terials and Methods. Aliquots of a nonionic detergent extract of labeled
cells (N3 x 108 cpm in a volume of 0.12 ml) were subjected to immuno-
precipitation analysis with no addition (lane 1), mAb 9.3 (5 ug, lane 2),
B7 Ig (10 Wg, lane 3), or chimeric L6 (10 lAg, lane 4) . After precipitation
ofantigen-antibody complexes using formalin-fixed Staphylococcus aurew,
extracts were then subjected to a second immunoprecipitation analysis with
no addition (lane 5), mAb 9 .3 (5 fag, lane 6), or B7 Ig (10 Icg, lane 7) .
Washed immunoprecipitates were analyzed by SDS-PAGE (5-15% acryl-
amide gradient) under reducing (+ #-ME, lanes 1-7) or non-reducing
conditions (- /3-ME, lanes 8 and 9), the gel was dried, and subjected
to autoradiography.
tity ofB7 Ig-binding proteins by immunoprecipitation analysis
of 1251-surface-labeled cells (Fig. 4 B). Both mAb 9.3 and
B7 Ig immunoprecipitated aMr , v45,000 protein under re-
ducing conditions and M, "45,000 and "90,000 proteinsunder nonreducing conditions, with the latter form being
more prominent. The Mr "45,000 protein found in the
sample precipitated with chimeric mAb L6 was due to spill-
over and was not seen in other experiments. mAb 9.3 was
more effective at immunoprecipitation than B7 Ig, in agree-
ment with thegreater affinity of the mAb (Fig. 3). Identical
results were obtained when CD28+ CHO cells were used
for immunoprecipitation analysis. Preclearing of CD28 by
immunoprecipitation with mAb 9.3 also removed B7 Ig-
precipitable material, indicating that both mAb 9.3 and B7
Ig bound the same 1251-labeled protein. Taken together, the
results in this section indicate that CD28 is themajorreceptor
for B7 Ig on PHAactivated T cells.
B7-Binding to CD28 Blocks CD28-mediated Adhesion.
￿
mAbs
to CD28 have potent biological activities on T cells, sug-
gesting that interaction of CD28 with its natural ligand(s)
may also have important functional consequences. As a first
step in determining functional consequences of interaction
betweenB7 and CD28, we asked whetherB7 Ig couldblock
the CD28-mediated adhesion assay (20). As shown in Fig.
5, B7 Ig blocked C1328-mediated adhesion somewhat less
effectively than mAb 9.3 (half-maximal inhibition at 200nM
as compared with 10 nM for mAb 9.3). The relative effec-
tiveness ofthese molecules at inhibiting CD28-mediated adhe-
sion was similar to theirrelative binding affinities in compe-
tition binding experiments (Fig. 3 A). CD28 Ig failed to
inhibit CD28-mediated adhesion at concentrations of up to
950nM (datanotshown), suggesting that much higher levels
of CD28 Ig were required to compete with the high local
concentrations of CD28 present on transfected cells.
B7 Costimulates TCellProliferation.
￿
We next investigated
whether triggering of CD28 by B7 was costimulatory for
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Figure 5.
￿
B7 Ig specifically inhibits CD28-mediatedadhesion. Theadhe-
sion of 5tCr-labeled PM lymphoblastoid cells to monolayers of CD28+
CHO cells was measured as described previously (20) in the presence of
theindicated amounts ofmAb9.3 or B7 Ig. Data are expressed as a per-
centage of cellsbound in theabsence ofcompetitor (40,000 cpm or -1.1
x 105 cells). Each point represents themean of triplicate determinations;
coefficients of variation were 425%.
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Table 1.
￿
B7 Ig Is Costimulatory with A11ti-CD3for Proliferation
ofPeripheral Blood Lymphocytes
PBL were isolated andcultured in the presence of theindicatedcostimu-
lators of Tcell proliferation. Anti-CD3 stimulation was with mAbG19-4
at 1 t~g/ml in solution. ForCD28 stimulation, mAb 9.3 or B7 Ig were
addedin solution at 1 hg/ml, or after immobilization on theculture wells
by pre-incubation of proteins at 10 ug/ml in PBS for 3 h at 23°C and
then washingthe culture wells. B7+ CHO and controldhfr+ CHO cells
were irradiated with 1,000 rad before mixing with PBL at a 4:1 ratio
of PBL/CHO cells. After culture for 3 d, proliferation was measured
by uptake of [3H]thymidine for 5 h. Values shown are means of deter-
minations from quadruplicate cultures (SEM <15%).
Tcell proliferation. Theabilityof B7 Ig to costimulate prolifer-
ation of PBL together with anti-CD3 was first explored. In
several experiments, B7 Ig in solution at concentrations of
1-10 1&g/ml showed only amodest enhancement of prolifer-
Table 2.
￿
B7 is Directly Stimulatory for Proliferation of
PHA Blasts
PHA blasts were cultured at 50,000 cells/well with varying amountsof
irradiated CHOcell transfectants. After2dofculture, proliferation was
measured by a 5-h pulse of [3H]thymidine. Shown are means of quad-
ruplicate determinations (SEM <15%). Background proliferation of PHA
blasts without added CHO cells was 11,200 cpm. [3H]Thymidine in-
corporation by irradiated B7+ CHO and CD5+ CHO cells alone was
<1,800 cpmat each cell concentrationandhas been subtracted from the
values shown.
Exp. CD28 stimulation
[3H]-T incorporation
- Anti-CD3 +Anti-CD3
cpm x 10-3
1 None 0.1 26.0
mAb 9.3 (solution) 0.3 156.1
mAb 9.3 (immobilized) 0.1 137.4
B71g (immobilized) 0.1 174.5
2 None 0.2 19.3
mAb 9.3 (solution) 0.4 75.8
B7+ CHO cells 9.4 113.9
dhfr + CHO cells 23.8 22.1
T cells/CHO cells
['H]-T
+B7+ CHO
incorporation
+CD5+ CHO
cpm x 10-3
25:1 92.7 15.5
50:1 135.4 19.5
100:1 104.8 16.8
200:1 90,3 17.7
400:1 57.0 13 .7
800:1 42.3 17.6Table 3.
￿
Stimulation of Proliferation ofPHA Blasts by B7+
CHO Cells Is Inhibited by CD28- or B7- specific mAbs
PHA blasts were stimulated as described in Table 2 with irradiated CHO
cells at a ratio of 100:1 T cells/CHO cells . mAbs were added at 10,ug/ml
at the beginning of culture . mAb LB-1 (21) is an isotype-matched con-
trol for mAb BB-1 . Proliferation was measured by uptake of [3H]-
thymidine during a 5-h pulse after2dofculture . Values represent means
of quadruplicate cultures (SEM <15%) .
Figure 6.
￿
B7 stimulates accumulation of IL2 mRNA . PHA blasts (5
x 10~ were mixed with transfected CHO cells (at a ratio of 40 :1 T
cells/CHO cells), and/or mAbs as indicated . mAb9.3 was used at 10 ug/ml.
mAbBB-1 (20 14g/ml) was added 1 h before addition of B7'CHO cells.
WhenmAb 9.3 was crosslinked, goat anti-mouse Ig (40 ftg/ml) was added
10 min after addition ofmAb9.3 . Cells were incubated for 6h at 37°C,
RNA was isolated and subjected to RNAblot analysis, using 32plabeled
11,2 or GAPDH probes.
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ation even though the anti-CD28mAb 9.3 was effective . Be-
cause CD28 crosslinking has been identified as an important
determinant of CD28 signal transduction (31), B7 Ig was
also compared to 9.3when immobilized on plastic wells (Table
1, Exp . 1) . Under these conditions, B7 Ig was able to en-
hance proliferation and compared favorably with mAb 9.3 .
B7+ CHO cells also were tested and compared with con-
trol dhfr+ CHO cells for costimulatory activity on resting
lymphocytes (Table 1, Exp . 2) . In this experiment, prolifera-
tion was seen with dhfr+ CHO cells in the absence of anti-
CD3 mAb because of residual incorporation of [3H]thymi-
dine after irradiation of these cells (data not shown) . This
stimulation was not enhanced by anti-CD3 mAb and was
not seen in other experiments (Tables 2 and 3) where trans-
fectedCHO cells were added at lower ratios. However, B7+
CHO cells were very effective at costimulation with anti-
CD3 mAb, indicating that cell surface B7 had similar ac-
tivity in this assay as anti-CD28 mAbs .
We also tested whether B7+ CHO cells could directly
stimulate proliferation of resting PHA blasts which respond
directly to CD28 crosslinking by mAb 9.3 . Again, the B7+
CHO cells were very potent in stimulating proliferation (Table
2) and were able to do so at very low cell numbers (PHA
blast:B7+ CHO ratios of>800:1) . The control CD5+ CHO
cells did not possess a similar activity . (In a number ofdifferent
experiments neither dhfr+ CHO, CD5+ CHO, nor CD7+
CHO cells stimulated T cell proliferation. These were there-
fore used interchangeably as negative controls for effects in-
duced byB7+ CHO cells) . The stimulatory activity ofB7+
CHO was further shown to result from CD28/B7 interac-
tion, since mAb BBl inhibited stimulation by the B7+
CHO cells without affecting background proliferation in the
presence ofCD7+ CHO cells (Table 3) . mAb LB-1 (21), an
IgMmAb to a different B cell antigen, did not inhibit prolifer-
ation . mAb 9.3 (Fab fragments) inhibited proliferation in-
duced by B7+ CHO but not background proliferation seen
with CD7+ CHO cells . The experiments show that B7 is
able to stimulate signal transduction and augment T cell ac-
tivity by binding to CD28, but that crosslinking is required
and B7 expressed on the cell surface is most effective.
B7 Stimulates IL2 mRNA Accumulation .
￿
We also inves-
tigated effects of CD28/B7 interactions on IIr2 production
by analyzing transcript levels in PHA-blasts stimulated with
B7+ CHO cells or CD7+ CHO cells . RNA was prepared
from stimulated cells and tested byRNA blot analysis for
the presence of IIr2 transcripts (Fig. 6) . B7+ CHO cells, but
not CD7+ CHO cells, induced accumulation of IL2 tran-
scripts. Induction by B7+ CHO cells was partially blocked
by mAb BB-1. Induction by B7+ CHO cells was slightly
better than achieved by mAb 9.3 in solution, but less effec-
tive than mAb 9.3 after crosslinking with goat anti-mouse
Ig. Thus, triggering ofCD28 by cell surfaceB7 on apposing
cells stimulated 11,2 mRNA accumulation .
Discussion
We have used soluble Ig CGy fusions of both CD28 and
B7 to measure the strength of their interaction . The apparent
Stimulation mAb [3H]-T incorporation
cpm x 10 -3
None None 10.8
B7+ CHO None 180
B7+ CHO 9.3 Fab 132
B7+ CHO BB-1 98.3
137* CHO LB-1 196
CD7+ CHO None 11 .5
CD7+ CHO 9.3 Fab 10.0
CD7+ CHO BB-1 10.0
CD7+ CHO LB-1 11.3Ka value for this interaction (ti200 nM) is within the range
of affinities observed for mAbs (2-10,000 nM ; reference 32)
and compares favorably with the affinities estimated for other
lymphoid adhesion molecules . Schneck et al . (33) estimated
the affinity (Kd -100 nM) between a murine T cell hy-
bridoma TCR and soluble alloantigen (class IMHC mole-
cules) . A Kd of 400 nM was measured between CD2 and
LFA3 (34) . The affinity of CD4 for class II MHC, while
not measured directly, was estimated (35) to be >10,000 times
lower than the affinity ofgp120-CD4 interactions (Kd = 4
nM; reference 36) . Thus, the affinity of B7 forCD28 appears
greater than affinities reported for some other lymphoid adhe-
sion systems.
The degree to which the apparent Kd ofCD28/B7 inter-
action reflects their true affinity, as opposed to their avidity,
depends on the valency and/or aggregation of the fusion pro-
tein preparations . In preliminary experiments, we examined
the degree of aggregation of these preparations by size frac-
tionation (TSKG3000SW column eluted with PBS) . Under
these conditions, B7 Ig eluted atMr "350,000, and CD28
Ig at M, -300,000. Both proteins thus behaved in solution
as larger molecules than they appeared by SDS-PAGE (Fig .
1), suggesting that they may form higher aggregates . Alter-
natively, these results may indicate that both fusion proteins
assume extended conformations in solution, resulting in large
Stokes radii . Regardless, the interaction we measured using
soluble proteins probably underestimates the true avidity be-
tweenCD28 and B7 in their native membrane-associated state.
The relative contribution of different adhesion systems to
the overall strength ofT cell-B cell interactions is not easily
gauged, but is likely a function of both affinity/avidity and
the densities on apposing cell surfaces of the different receptors
and counter-receptors involved . Since bothCD28 and B7 are
found at relatively low levels on resting lymphoid cells (16,
22), they may be less involved than other adhesion systems
(7) in initiating intercellular interactions. The primary role
of CD28/B7 interactions may be to maintain or amplify a
response subsequent to induction of these counter-receptors
on their respective cell types .
While occupancy or crosslinking of the T cell antigen
receptor is sufficient to initiate a T cell immune response,
full activation requires additional costimulatory signals . In
some cases, soluble molecules such as IL-1 can provide
costimulatory activity, but in other cases the nature of the
molecule(s) involved is unclear (8, 9) . Schwartz (9) has re-
cently reviewed evidence for a costimulatory activity on
antigen-presenting cells whichmay determine whetherTCR
occupancy leads to a productive or anergic response in mu-
rine T clones . This activity appears to require cell-cell con-
tact, leads to increased IL2 production, and may operate
through a different signal-transducing pathway than theTCR
(9) . All of these characteristics are shared with the CD28
pathway (reviewed in reference 14), leading to the intriguing
possibility thatCD28 may be one ofthese functionally defined
costimulatory molecules. In agreement with this possibility,
is the finding by Ledbetter et al . (31) that anti-CD28 mAb
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can partially overcome inhibition ofT cell proliferation in-
duced by internalization of theTCR . Studies of the involve-
ment ofCD28/B7 interactions in various experimental systems
will be required to fully evaluate the role of these costimula-
tory interactions .
Binding ofB7 to CD28 on T cells was costimulatory for
T cell proliferation (Tables 1-3), suggesting that some of the
biological effects of anti-CD28mAbs result from their ability
to mimicT cell activation resulting from natural interaction
between CD28 and its counter-receptor, B7 . mAb 9.3 has
greater affinity for CD28 than does B7 Ig (Figs. 4 and 5),
whichmay account for the extremely potent biological effects
of thismAb (14) in costimulating polyclonalT cell responses.
Surprisingly, however, anti-CD28 mAbs are inhibitory for
antigen-specific T cell responses (15, 16) . This may indicate
that antigen-specific T cell responses are dependent upon
costimulation viaCD28/B7 interactions, and that inhibition
therefore results from blocking of CD28 stimulation. De-
spite the inhibition, CD28 must be bound by mAb under
these conditions, implying that triggering by mAb is not
always equivalent to triggering by B7 . Although mAb 9.3
has higher apparent affinity for CD28 than B7 (Fig . 3), it
may be unable under these circumstances to induce the op-
timal degree of CD28 clustering (31) for stimulation .
CD28/B7 interactions may also be important for B cell
activation and/or differentiation . We have recently observed
that mAbs 9.3 and BB-1 block T cell-induced Ig produc-
tion by B cells (N . Damle, P. S . Linsley, and J. A . Ledbetter,
unpublished results) . This blocking effect may be due in part
to inhibition by these mAbs of production of T,;derived B
cell-directed cytokines, but may also involve inhibition of
B cell activation by interfering with direct signal transduc-
tion via B7 . These results suggest that cognate activation of
B lymphocytes, as well as T lymphocytes, is dependent
upon interaction between CD28 and B7 .
The mechanism of 11,2 transcript induction in T cells by
B7+ CHO cells (Fig . 6) is not currently known . It is well
known that mRNAs for cytokines and other inflammatory
mediators are characterized by the presence in their 3' un-
translated regions of AU-rich motifs (37), which control
mRNA stability (38) . Studies by Lindsten et al . (19) showed
that anti-CD28 mAbs stimulated production of several T
cell-derived cytokines by stabilizing transcripts for these mol-
ecules. However, as discussed by June et al . (14), anti-CD28
mAbs may also enhance transcription of IL-2 mRNA .
Whatever the mechanism of transcript accumulation by
CD28/B7 interactions, regulation of cytokine production by
cell-cell contact has also been shown in other systems (39) .
Many effector functions ofT lymphocytes are cytokine medi-
ated (40), and control points in the synthetic pathways of
these molecules are therefore extremely important . As dys-
functional cytokine production has been implicated as a con-
tributing factor in several human diseases (40), it will be im-
portant to determine how B7/CD28 interactions regulateT
cell cytokine production in various pathological states .We thank Mark Stebbins for advice on purification of fusion proteins and for analytical HPLC analyses
of these proteins, Margit Gayle for help with cDNA synthesis andRNA from the chimeric L6 transfec-
toma, Virginia Smith foramino acid analyses, DerekHewgill for help with the FRCS, Dr. SteveKanner
for a critical review ofthe manuscript, andDr . Karl Erik Hellstrom forcontinued support andencouragement .
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